Abstracts tagged "risk assessment"

Abstract Number: 0293 • ACR Convergence 2024
Assessment of Skin Cancer Risk in Autoimmune Diseases: A Multivariate Analysis Using a National Inpatient Database
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Autoimmune diseases are known to be associated with an increased risk of many types of cancers. This study investigates the association between different types…
Abstract Number: 0859 • ACR Convergence 2024
Incidence of Aortic Aneurysm, Dissection, or Rupture Among Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Kylie Carlson¹, Mahmut Kaymakci², Sebastian E. Sattui³ and Michael Putman⁴, ¹Medical College of Wisconsin, Milwaukee, WI, ²Mayo Clinic, Rochester, MN, ³University of Pittsburgh, Pittsburgh, PA, ⁴The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Patients with polymyalgia rheumatica (PMR) may develop overt giant cell arteritis (GCA), but “subclinical” large vessel inflammation has also been reported in patients with…
Abstract Number: 1725 • ACR Convergence 2024
Exploring Risks of Polymyalgia Rheumatica (PMR), Giant Cell Arteritis (GCA) and Complications While Receiving Immune Checkpoint Inhibitors: Comparative Analysis
Irakli Tskhakaia and Arthur Lau, Jefferson Einstein Hospital, Philadelphia, PA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, offering significant benefits in various malignancies. However, these therapies can induce immune-related adverse events (irAEs), including…
Abstract Number: 2469 • ACR Convergence 2024
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Stefano Di Donato¹, Vishal Kakkar², Silvia Bellando-Randone³, Marco Matucci-Cerinic⁴ and Francesco Del Galdo², and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 1000 • ACR Convergence 2024
Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Hafsah Nabi², Dorte Vendelbo Jensen³, Jens Pedersen⁴, Oliver Hendricks⁵, Anne Gitte Loft⁶, Ada Colic⁷, Kamilla Danebod³, Salome Kristensen⁸, Heidi Munk⁹, Niels Lomborg¹⁰, Natalia Manilo¹¹, Stavros Chrysidis¹², Søren Just¹³, Asta Linauskas¹⁴, Pil Højgaard¹⁵, Pia Høger Thygesen¹⁶, Malene Kildemand¹⁷, Rene Drage Oestgaard¹⁸, Merete Hetland¹⁹ and Bente Glintborg²⁰, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ⁵Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, ⁷Department of Rheumatology, Zealand University Hospital, Koege, Denmark, ⁸Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, ¹¹Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹²Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ¹³Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ¹⁴Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ¹⁵Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, ¹⁶Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁷Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, ¹⁸Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ²⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
Abstract Number: 1874 • ACR Convergence 2024
Validation Analysis of the Expanded Risk Score for Rheumatoid Arthritis in a Multicentre Italian Cohort
Fabio Cacciapaglia¹, Gian Luca Erre², Matteo Piga³, Elena Bartoloni Bocci⁴, Andreina Manfredi⁵, Ennio Giulio Favalli⁶, Maria Sole Chimenti⁷, Serena Guiducci⁸, Eleonora Celletti⁹, Addolorata Corrado¹⁰, Alessandro Giollo¹¹, SIMONE PARISI¹², Ivan Giovannini¹³, Elisa Gremese¹⁴, Francesca Romana Spinelli¹⁵, Garifallia Sakellariou¹⁶, Ombretta Viapiana¹⁷ and Fabiola Atzeni¹⁸, and Cardiovascular Obesity and Rheumatic DISeases Study Group of the Italian Society of Rheumatology, ¹Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ²Rheumatology Unit - University of Sassari, Sassari, Italy, ³Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁴Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁵University of Modena and Reggio Emilia, Modena, ⁶ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ⁷Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ⁸University of Florence, Pistoia, Italy, ⁹Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹⁰Rheumatology Unit, University of Foggia, Foggia, Italy, ¹¹Azienda Ospedale Università Padova, Padova, Padua, Italy, ¹²Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁵Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁶Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ¹⁷Rheumatology Unit, University of Verona, Verona, Italy, ¹⁸University of Messina, Italy, Messina, Italy
Background/Purpose: This study aimed to compare the performance of three validated algorithms for 10-year global cardiovascular risk stratification (GCVR): the European Systemic Coronary Risk (SCORE-2)…
Abstract Number: 2492 • ACR Convergence 2024
ANCA Associated Tracheobronchial Disease
Megan Sullivan¹, Maximiliano Diaz Menindez², Ronald Butendieck³, hassan baig⁴, Anushka Irani⁵, Benjamin Wang³, Florentina Berianu⁵, Carolyn Mead-Harvey⁶, Andy Abril⁵ and Vikas Majithia⁴, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic School of Graduate Medical Education, Phoenix, AZ, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶Mayo Clinic, Scottsdale, AZ
Background/Purpose: Tracheobronchial disease is a common manifestation of ANCA associated vasculitis (AAV). However, outcomes data is commonly unreported in prospective studies. We performed a retrospective…
Abstract Number: 0446 • ACR Convergence 2023
Review of Rheumatoid Arthritis Treatment Landscape During the COVID-19 Pandemic
Rachel Connolly¹, MamTing Thoo², Elizabeth Baynton³ and Denise Baldock³, ¹Ipsos, New York, NY, ²Ipsos SDN BHD, Kuala Lumpur, Malaysia, ³Ipsos MORI UK, London, United Kingdom
Background/Purpose: During the COVID-19 pandemic, guidelines were amended with respect to the prescribing of biologic/tsDMARD usage to treat rheumatoid arthritis (RA). In addition, regulatory reviews…
Abstract Number: 1768 • ACR Convergence 2023
The Dynamics of the Gut Microbiome in Rheumatoid Arthritis Susceptibility: A Cross-Sectional and Longitudinal Observational Study
Christopher Rooney¹, Ian Jeffery², Kulveer Mankia³, Mark Wilcox¹ and Paul Emery⁴, ¹University of Leeds, Leeds, United Kingdom, ²4D Pharma plc, Cork, Ireland, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Multiple compositional shifts of gut microbiota have been identified within the rheumatoid arthritis (RA) disease continuum, encompassing both established RA and at-risk individuals (including…
Abstract Number: 0571 • ACR Convergence 2023
A Polygenic Risk Score for Systemic Lupus Erythematosus (SLE) Discriminates Between Patients with Lupus and Individuals Without Lupus and a Positive Antinuclear Antibody Test
Gul Karakoc¹, Ge Liu¹, Jacy Zanussi², Cecilia Chung², Jorge Gamboa¹, Jonathan Mosley¹, Nancy Cox¹, C. Michael Stein¹ and Vivian Kawai¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of Miami, Miami, FL
Background/Purpose: A positive ANA (ANA-POS) test is present in almost all patients with SLE and is also frequently present in other autoimmune (AI) diseases and…
Abstract Number: 1950 • ACR Convergence 2023
Thromboembolic Risk Associated with Intravenous Immune Globulin Use in Patients with Idiopathic Inflammatory Myopathy: A Large Database Study
Rohan Mehta¹, Mike Putman² and Didem Saygin³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Intravenous immune globulin (IVIG) recently received regulatory approval for the treatment of dermatomyositis, one of the idiopathic inflammatory myopathies (IIM). The pivotal randomized trial…
Abstract Number: 0620 • ACR Convergence 2023
Physical and Mental Health in Early Systemic Sclerosis: Baseline Results for Patient-Reported Outcomes Measurement Information System-29 from the Collaborative National Quality and Efficacy Registry
Isha Lamba¹, Ashima Makol², Dinesh Khanna³, John VanBuren⁴, Angela Child⁴, Jessica Alvey⁴, Shervin Assassi⁵, Elana Bernstein⁶, Flavia Castelino⁷, Lorinda Chung⁸, Luke Evnin⁹, Tracy Frech¹⁰, Faye Hant¹¹, Laura Hummers¹², Kimberly Lakin¹³, Dorota Lebiedz-Odrobina¹⁴, Yiming Luo¹⁵, Jerry Molitor¹⁶, Duncan Moore¹⁷, Carrie Richardson¹⁸, Nora Sandorfi¹⁹, Ami Shah²⁰, Ankoor Shah²¹, Victoria Shanmugam²², Brian Skaug²³, Virginia Steen²⁴, Elizabeth Volkmann²⁵ and Jessica Gordon¹³, ¹New York Presbyterian Hospital/Weill Cornell Medical Centre, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of Michigan, Ann Arbor, MI, ⁴University of Utah, Salt Lake City, UT, ⁵University of Texas McGovern Medical School at Houston, Houston, TX, ⁶Columbia University, New York, NY, ⁷Massachusetts General Hospital, Boston, MA, ⁸Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁹Scleroderma Research Foundation, Brisbane, CA, ¹⁰Vanderbilt University Medical Center, Nashville, TN, ¹¹Medical University of South Carolina, Charleston, SC, ¹²Johns Hopkins University, Baltimore, MD, ¹³Hospital for Special Surgery, New York, NY, ¹⁴University of Utah, Cottonwood Heights, UT, ¹⁵Division of Rheumatology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Northwestern Memorial Hospital, Chicago, IL, ¹⁸Northwestern University, Riverside, IL, ¹⁹University of Pennsylvania, Philadelphia, PA, ²⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD, ²¹Duke University, Durham, NC, ²²Victoria Shanmugam, MD, Great Falls, VA, ²³Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²⁴Georgetown University School of Medicine, Washington, DC, ²⁵University of California Los Angeles, Los Angeles, CA
Background/Purpose: Patient-Reported Outcomes Measurement Information System-29 version 2.0 (PROMIS-29v2) is a patient-centered questionnaire used to assess health-related quality of life (HRQoL). PROMIS-29v2 has shown validity…
Abstract Number: 1996 • ACR Convergence 2023
Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Karla Miller¹, Melissa Steffen², Kimberly McCoy², Michelle Mengeling², Heather Davila², Shylo Wardyn² and Samantha Solimeo², ¹University of Utah School of Medicine, Salt Lake City, UT, ²Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA
Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
Abstract Number: 0633 • ACR Convergence 2023
Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
Min Hui¹, Xinwang Duan², Jiaxin Zhou³, Mengtao Li³, Qian Wang⁴, Jiuliang Zhao¹, Yong Hou¹, Dong Xu⁵ and xiaofeng Zeng⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College, Beijing, China
Background/Purpose: Systemic sclerosis (SSc) patients can develop progressive fibrosing interstitial lung disease (PF-ILD), linked to a poor outcome. This study aims to establish a reliable…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].